Investment House LLC Vertex Pharmaceuticals Inc Transaction History

Investment House LLC

$1.75 Billion
Q2 2024

A detailed history of Investment House LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Investment House LLC holds 825 shares of VRTX stock, worth $394,267. This represents 0.02% of its overall portfolio holdings.

Number of Shares

825

Previous 680 21.32%

Holding current value

$394,267

Previous $284,000 35.92%

% of portfolio

0.02%

Previous 0.02%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 22, 2024	BUY	$392.81 - $485.53 $56,957 - $70,401	145 Added 21.32%	825 $386,000
Q1 2024 May 02, 2024	BUY	$407.69 - $446.08 $40,769 - $44,608	100 Added 17.24%	680 $284,000
Q2 2023 Aug 08, 2023	BUY	$314.42 - $351.91 $182,363 - $204,107	580 New	580 $204,000
Q4 2021 Feb 09, 2022	SELL	$177.01 - $223.45 $1.91 Million - $2.41 Million	-10,795 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$181.39 - $202.99 $904,410 - $1.01 Million	-4,986 Reduced 31.59%	10,795 $1.96 Million
Q2 2021 Jul 20, 2021	BUY	$187.49 - $221.1 $27,186 - $32,059	145 Added 0.93%	15,781 $3.18 Million
Q1 2021 May 06, 2021	BUY	$207.02 - $241.31 $132,492 - $154,438	640 Added 4.27%	15,636 $3.36 Million
Q4 2020 Jan 13, 2021	BUY	$207.01 - $276.09 $395,389 - $527,331	1,910 Added 14.6%	14,996 $3.54 Million
Q3 2020 Nov 06, 2020	BUY	$255.65 - $303.1 $314,449 - $372,813	1,230 Added 10.37%	13,086 $3.56 Million
Q2 2020 Jul 13, 2020	BUY	$225.48 - $295.8 $1.24 Million - $1.62 Million	5,480 Added 85.95%	11,856 $3.44 Million
Q1 2020 Apr 08, 2020	BUY	$199.77 - $247.81 $1.27 Million - $1.58 Million	6,376 New	6,376 $1.52 Million

Others Institutions Holding VRTX

# of Institutions

1,707

Shares Held

226M

Call Options Held

1.2M

Put Options Held

1.59M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $123B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Investment House LLC, based on Form 13F filings with the SEC.

News

Stay updated on Investment House LLC with notifications on news.

Account

Investment House LLC Vertex Pharmaceuticals Inc Transaction History